Evidence map›Paper›PMID 27830062›Full record

ArticleF1000Research2016

Michael Mülleder, Kate Campbell, Olga Matsarskaia, Florian Eckerstorfer, Markus Ralser

Abstract read
In one paragraph

Article in F1000Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Developing a Novel and Optimized Yeast Model for Human VDAC Research.International journal of molecular sciences · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Michael Mülleder *Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK.
Kate Campbell *Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK.
Olga MatsarskaiaDepartment of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK.
Florian EckerstorferDepartment of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK.
Markus RalserDepartment of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK.

Funding

Wellcome Trust FC001134
6 · The paper itself

Abstract

Auxotrophic markers are useful tools in cloning and genome editing, enable a large spectrum of genetic techniques, as well as facilitate the study of metabolite exchange interactions in microbial communities. If unused background auxotrophies are left uncomplemented however, yeast cells need to be grown in nutrient supplemented or rich growth media compositions, which precludes the analysis of biosynthetic metabolism, and which leads to a profound impact on physiology and gene expression. Here we present a series of 23 centromeric plasmids designed to restore prototrophy in typical

Indexed as

auxotrophic markerscentromeric plasmidmetabolismSaccharomyces cerevisiaeself-establishing metabolically cooperating (SeMeCo) communities

Identifiers

PMID27830062
PMCPMC5081161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.